Pharmacokinetics of remoxipride and metabolites following a single oral dose of 14C-remoxipride

Remoxipride: pharmacokinetics and effect on plasma prolactin.

“…Remoxipride is a single enantiomer and no active metabo- (Widman et al, 1990). It is a low clearance drug with a plasma clearance of 112 ml min-' 1.73 m-2 and a non-renal elimination of 75%.…”

Influence of the dosing interval on prolactin release after remoxipride.

“…Remoxipride is a pure enantiomer which is eliminated both by metabolism (-75%) and renal excretion of unchanged drug (-25%). No active metabolites have been reported in man [38]. It is a low clearance drug with a plasma clearance of 106 + 17 ml min-, and with a bioavailability above 90%.…”

Online solid phase extraction with liquid chromatography–tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples

“…Intranasal delivery of remoxipride was investigated to directly target the brain. Intranasal delivery is a promising alternative for oral or parenteral administration, since it avoids the high first-pass clearance of remoxipride [8,[16][17][18]. All animal procedures were performed in accordance with Dutch laws on animal experimentation.…”

“…Therefore, Main et al [7] measured remoxipride in cerebral spinal fluid using the method described by Nilsson [4]. The earlier published analytical methods presented above [3][4][5][6][7][8] require rather large plasma or cerebral spinal fluid samples ranging from 0.5 to 2 ml, which can be obtained from humans in clinical studies (Table 1). In preclinical PK-PD studies, however, small laboratory animals are mostly used, thereby limiting the sample size.…”

“…de Ruiter [3] Nilsson [4,7,8] Chiou [5] DePuy [6] Sample volume plasma (ml) >0. 5 raphy (HPLC) with ultraviolet detection (UV).…”